Cost-utility analysis of palivizumab in Italy: results from a simulation model in the prophylaxis of respiratory syncytial virus infection (RSV) among high-risk preterm infants

• Asıl Yazarlar: Ravasio Roberto (Yazar), Chirico Gaetano (Yazar), Sbarigia Urbano (Yazar)
• Materyal Türü: Kitap
• Baskı/Yayın Bilgisi: BMC, 2009-02-01T00:00:00Z.
• Konular: article
• Online Erişim: Connect to this object online.

<p>Abstract</p> <p>Introduction</p> <p>The aim of this study was to assess the cost-utility of palivizumab versus no prophylaxis in the prevention of respiratory syncytial virus infection among high-risk preterm infants.</p> <p>Methods</p> <p>We...